tbuckley/cabot-search huggingface dataset:
ULTRAVIOLET RADIATION AND BASAL METABOLISM
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Use of Genetic Toxicology Data in U.S. EPA Risk Assessment: The Mercury Study Report as an Example
Authors: Rita Schoeny
Journal: Environmental Health Perspectives (1996)

Assessment of human health risks of environmental agents has often been limited to consideration of the potential for the agent to cause cancer or general systemic toxicity after long-term exposure.The U.S. Environmental Protection Agency (U.S. EPA) is increasingly moving toward the development of integrated assessments, which consider all potential health end points including developmental toxicity, neurotoxicity, immunotoxicity, reproductive effects, and germ cell muta- genicity.The U.S. EPA has a responsibility to assess risks to nonhuman species or ecosystems when appropriate data are available.An example of a recent integrated human health and ecologi- cal risk assessment can be found in the U.S. EPA Mercury Study Report to Congress.This report covers the following topics in separate volumes: an inventory of anthropogenic mercury emis- sions in the United States; an exposure assessment using measured and predicted values and including indirect dietary exposure; an evaluation of human health risks; an assessment of ecologic risk wherein water criteria are presented for several wildlife species; an overall integrated characterization of human and nonhuman risk; and a discussion of risk management considera- tions.In the evaluation of human health risk, genetic toxicology data were considered for three forms of mercury: elemental, inorganic (divalent), and methylmercury.These data were used in judgments of two types of potential health effects (carcinogenicity and germ cell mutagenicity).In assessment of potential carcinogenicity of inorganic and methylmercury, genetic toxicity data were key.Data for clastogenicity in the absence of mutagenicity supported the characterization of inorganic and methylmercury as materials that produce carcinogenic effects only at high, toxic doses.The evidence for clastogenicity, coupled with information on metabolism and distribution, resulted in a judgment of a moderate degree of concern (or weight of evidence) that inorganic mercury can act as a human germ cell mutagen.For methylmercury, the degree of concern for germ cell mutagenicity is high.
Social Medicine and Miscellany
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Standardization of antituberculosis drug resistance surveillance in Europe Recommendations of a World Health Organization (WHO) and International Union Against Tuberculosis and Lung Disease (IUATLD) Working Group
Authors: V. Schwbel, C.S.B. Lambregts-van Weezenbeek, M-L. Moro, F. Drobniewski, S.E. Hoffner, M.C. Raviglione, H.L. Rieder
Journal: European Respiratory Journal (2000)

Surveillance of antituberculosis drug resistance is an essential tool for evaluating the quality of tuberculosis control programmes. Consensus-based recommendations on uniform reporting of antituberculosis drug resistance surveillance data in Europe have been developed by a Working Group of the World Health Organization (WHO) and the International Union Against Tuberculosis and Lung Disease (IUATLD). Laboratories should use standardized methods for testing drug susceptibility with a quality assurance programme including national and international proficiency testing. The proportion of drug resistance, particularly resistance to isoniazid, rifampicin or both (multidrug resistance) among all definite, i.e. culture-positive, tuberculosis cases at the start of treatment is the major indicator of interest. It should be calculated separately among patients treated previously and among those who have never been treated with &gt; or = 1 month of combined antituberculosis drugs. The Working Group recommends that, in countries in which resources allow, laboratories report drug susceptibility test results on all isolates of the Mycobacterium tuberculosis complex. Test results of the specimen at the start of treatment and clinical data from the notification should be linked using a suitable identifier. Results should be presented by calendar year and analysed by age, sex, place of birth, site of disease and sputum smear results. In countries in which a routine system cannot be organized, representative surveys or sentinel systems are possible alternatives. In some countries, the annual prevalence of multidrug-resistant tuberculosis may be estimated through a national laboratory reporting system.
AUTO-DISPENSING.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Leiomyomatosis Cutis
Authors: S. Ross Fox
Journal: New England Journal of Medicine (1960)

LEIOMYOMATOSIS cutis is a rare dermatologic disorder typified by hyperplasia of one of the several smooth-muscle elements found in the skin. This entity was first recognized clinically by Virchow1 in 1854. Since then, several types of cutaneous leiomyoma have been described, each arising from a different site of smooth muscle in the cutis and subcutis. The purpose of this paper is to report a case of disseminated cutaneous leiomyoma arising from the erector pili muscles of the dermis. A therapeutic agent for the relief of pain caused by this disorder is suggested on the basis of experience with the following . . .
Irritable Uterus
Authors: F. W. Mackenzie
Journal: BMJ (1851)

A PAINFUL condition of the uterus, when not occasioned by displacement, inflammation, or any appreciable organic disease, constitutes the hysteralgia of some authors, and the irritable uterus of Dr. Gooch.It is met with in practice in various degrees of intensity, from slight un- easiness to a disease characterized by the most excruciating suffering.In its severest forms it is comparatively seldom met with; but, other- wise, it cannot be regarded as an unusual disease.Although it would essentially appear to consist in a mere lesion of innervation, and to be a very simple and remediable disorder, it is often found to be the re- verse; and in some instances has baffled the resources and the ingenuity of the most experienced physicians.I propose, in the present conununication, to draw attention to some facts which have come under my observation in relation to this disease, and to submit such inferences as appear to me to be deducible from them.The slighter forms of this malady are characterized by pain in the uterine region, increased by standing or walking, and somewhat re- lieved by lying down.The pain extends, or rather radiates from the uterus to the groins, hips, thighs, and loins.A sensation of bearing down of the womb is often felt; there is frequently leucorrhoea and sometimes dysmenorrhcea.On a digital examination, the uterus is found to be extremely sensitive to the touch, but it is neither displaced, nor perceptibly diseased.The constitutional derangement attending this uneasiness is seldom of a febrile character; on the contrary, the general health is for the most part depressed, the circulation is languid, the pulse feeble, and the condition of the nervous system is that of weakness and iritability.The digestive organs, so far as I have observed, are seldom unaffected; they are generally in an irritable and disordered condition, and their secretions are either faulty or defi- cient.On inquiry into the antecedent circumstances of the patient, it VOL.III.
Left ventricular structure and function in untreated, treated but uncontrolled, and controlled hypertension: The strong heart study Marilyn L. Wright, Richard B. Devereux, Mary J. Roman, Lyle Best, Richard R. Fabsitz, Elisa T. Lee, Barbara V. Howard. Weill Cornell Medical Center, New York, NY
Journal: Journal of the American College of Cardiology (2001)
The Relationship of Histology to Prognosis in Carcinoma of the Thyroid
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 1723: Elucidation of novel therapeutic targets for acute myeloid leukemias with <i>RUNX1</i>-<i>RUNX1T1</i> fusion
Authors: Jae Won Yun, Yoon Kyung Bae, So Yeong Cho, Hee-Jin Kim, Do-Hyun Nam, Sun-Hee Kim, Sejong Chun, Kyeung Min Joo, Hye Won Lee, Woong-Yang Park
Journal: Cancer Research (2019)

Abstract The RUNX1-RUNX1T1 fusion is a frequent chromosomal alteration in acute myeloid leukemias (AMLs). Although RUNX1-RUNX1T1 fusion protein has pivotal roles in the development of AMLs with the fusion, RUNX1-RUNX1T1 fusion protein is difficult to target since it lacks kinase activities. Here, we used a sophisticated bioinformatic tool to elucidate targetable signaling pathways in AMLs with RUNX1-RUNX1T1 fusion. After analysis of 93 AMLs from the TCGA database, the expressions of 293 genes were significantly correlated with the expression of the RUNX1-RUNX1T1 fusion gene. Based on the 293 genes, the COX, VEGFR, PDGFR, and FGFR pathways are predicted to be specifically activated in AMLs with RUNX1-RUNX1T1 fusion. Compared with the AML cells without the fusion, the specific activations of the AML cell lines with RUNX1-RUNX1T1 fusion were confirmed by the increased phosphorylation of VEGFRs, PDGFRs, and FGFRs. Moreover, the in vitro proliferation of AML cells with RUNX1-RUNX1T1 fusion decreased significantly more than that of AML cells without the fusion when the pathways were inhibited pharmacologically. The results indicate that novel targetable signaling pathways could be identified by the analysis of the gene expression features of AMLs with non-targetable genetic alterations. The elucidation of specific molecular targets for AMLs that have a specific genetic alteration would promote personalized treatment of AMLs and improve treatment outcomes for AML patients in clinic. Note: This abstract was not presented at the meeting. Citation Format: Jae Won Yun, Yoon Kyung Bae, So Yeong Cho, Hee-Jin Kim, Do-Hyun Nam, Sun-Hee Kim, Sejong Chun, Kyeung Min Joo, Hye Won Lee, Woong-Yang Park. Elucidation of novel therapeutic targets for acute myeloid leukemias with RUNX1-RUNX1T1 fusion [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1723.
Incidence of fatigue symptoms and diagnoses presenting in UK primary care from 1990 to 2001
Journal: Journal of the Royal Society of Medicine (2005)

Little is known about whether the incidence of symptoms of fatigue presented in primary care, and the consequent diagnoses made, change over time.The UK General Practice Research Database was used to investigate the annual incidence of both fatigue symptoms and diagnoses recorded in UK primary care from 1990 to 2001.The overall incidence of all fatigue diagnoses decreased from 87 per 100 000 patients in 1990 to 49 in 2001, a reduction of 44%, while postviral fatigue syndromes decreased from 81% of all fatigue diagnoses in 1990 to 60% in 2001.Chronic fatigue syndrome (CFS) and myalgic encephalomyelitis (ME) together increased from 9% to 26% of all fatigue diagnoses.The incidence of fibromyalgia increased from less than 1 per 100 000 to 35 per 100 000.In contrast, there was no consistent change in the incidence of all recorded symptoms of fatigue, with an average of 1503 per 100 000, equivalent to 1.5% per year.CFS/ME and fibromyalgia were rarely diagnosed in children and were uncommon in the elderly.All symptoms and diagnoses were more common in females than in males.The overall incidence of fatigue diagnoses in general has fallen, but the incidence rates of the specific diagnoses of CFS/ME and fibromyalgia have risen, against a background of little change in symptom reporting.This is likely to reflect fashions in diagnostic labelling rather than true changes in incidence.
Impotence following anesthesia for elective circumcision
Authors: J. M. Palmer
Journal: JAMA (1979)

SEXUAL impotence is a distressing problem in any age group. Acquired impotence occurs rarely after massive pelvic trauma but otherwise results from extirpative surgery for a malignant neoplasm. In the young, sexually active male, unexpected impotence is catastrophic. We recently observed two young men, both of whom were rendered impotent apparently by local anesthesia for elective circumcision. <h3>Patients and Methods</h3><h3>Case 1.—</h3> In November 1976 a 24-year-old man was seen who had a loss of sexual potency since an elective circumcision performed 18 months previously. His erections were normal at the base and the glans but flaccid in the distal part of the shaft and of insufficient quality to allow penetration. There were no abnormalities disclosed by examination of the phallus. Photographs taken by the patient at the time of sexual excitement were consistent with his description. Findings of the remainder of the physical examination were normal. Corpus cavernography was
JAMA Dermatology
Journal: JAMA Dermatology (2017)

Mission Statement JAMA Dermatology publishes information concerning the skin, its diseases, and their treatment.Its mission is to explicate the structure and function of the skin and its diseases and the art of using this information to deliver optimal medical and surgical care to the patient.We attempt to enhance the understanding of cutaneous pathophysiology and improve the clinician's ability to diagnose and treat skin disorders.This journal has a particular interest in publishing clinical and laboratory studies that reveal new information pertinent to the interests and needs of the medical dermatologist, dermatologic surgeon, and all those concerned with state-of-the-art care of cutaneous disease.We believe that knowledge derived from well-designed clinical trials and studies of cost-eff ectiveness are especially important for improving the practice of dermatology.Studies that increase the understanding of the outcome of treatment or the means by which the burden of dermatologic disease can be measured and reduced to promote the health of patients with skin disease will receive special priority.The journal regularly publishes reports on clinical investigations, editorials, and reviews.It also features reports and discussions on clinicopathologic correlations; clinical disorders of unique didactic value; pharmacologic, medical and surgical therapeutics; and ethical, moral, socioeconomic, and political issues.
Episiotomy
Authors: G. S. N. Dow
Journal: BMJ (1944)

The antiemetic properties of marijuana are well known, but there is increasing evidence of its paradoxical hyperemetic effects on the gastrointestinal tract and central nervous system, known as ‘cannabinoid hyperemesis syndrome’ (CHS). We report a case of CHS encountered in our outpatient clinic. We also completed a review of the literature using PubMed in patients over 18 years of age with CHS. Understanding the diagnostic criteria and risk factors associated with CHS may reduce the ordering of unnecessary and expensive investigations, and pursuing inappropriate medical and surgical treatments. Ultimately, abstaining from cannabis use leads to resolution of symptoms in the majority of patients.
Improving Palliative Care
Authors: Diane E. Meier
Journal: Annals of Internal Medicine (1998)

Letters15 March 1998Improving Palliative CareDiane E. Meier, MD, R. Sean Morrison, MD, and Christine K. Cassel, MDDiane E. Meier, MDMount Sinai School of Medicine; New York, NY 10029Search for more papers by this author, R. Sean Morrison, MDMount Sinai School of Medicine; New York, NY 10029Search for more papers by this author, and Christine K. Cassel, MDMount Sinai School of Medicine; New York, NY 10029Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-128-6-199803150-00031 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We agree with Dr. Fitzgerald's concerns about the hazards of medicalization of the dying process and the risk that important experiences and opportunities for patients and their loved ones may be compromised by an almost exclusive focus on end-of-life care as a series of medical problems requiring resolution [1]. To the contrary, the patient and family have the central roles in the process and do the major emotional, existential, and spiritual work of the last phase of life. Nevertheless, most dying patients have distressing physical and psychological symptoms [2, 3] that can be effectively alleviated by appropriate medical ...References1. Morrison RS, Meier DE, Cassel CK. When too much is too little. N Engl J Med. 1996; 335:1755-9. Google Scholar2. Seale C, Cartwright A. The Year before Death. Brookfield, VT: Ashgale Publishing; 1994. Google Scholar3. Ingham J, Portenoy R. Symptom assessment. Hematol Oncol Clin North Am. 1996; 10:21-39. Google Scholar Author, Article, and Disclosure InformationAffiliations: Mount Sinai School of Medicine; New York, NY 10029 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byConceptual framework: Entrepreneurial-management-competence and its effects on task complexity and the success of new firms 15 March 1998Volume 128, Issue 6Page: 510KeywordsEmotionsHealth care sectorMedical educationPalliative careQuality of life ePublished: 15 August 2000 Issue Published: 15 March 1998 Copyright & PermissionsCopyright © 1998 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
The State Medical Association and Continuing Medical Education
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
International Union Against Cancer (UICC) Workshop on Doctor Involvement in Public Education About Cancer
Journal: JNCI Journal of the National Cancer Institute (1984)

International Union Against Cancer (UICC) Workshop on Doctor Involvement in Public Education About Cancer Get access JNCI: Journal of the National Cancer Institute, Volume 72, Issue 5, May 1984, Page 1210, https://doi.org/10.1093/jnci/72.5.1210-a Published: 01 May 1984
Manuscripts Approved for JNCI, September 10 to October 10, 1963
Journal: JNCI Journal of the National Cancer Institute (1963)

Manuscripts Approved for JNCI, September 10 to October 10, 1963 Get access JNCI: Journal of the National Cancer Institute, Volume 31, Issue 5, November 1963, Page 1309, https://doi.org/10.1093/jnci/31.5.1309 Published: 01 November 1963